Cover Image
市場調查報告書

胰岛细胞癌 (胰島素瘤) :全球臨床實驗趨勢

Islet Cell Carcinoma (Insulinoma) Global Clinical Trials Review, H1, 2015

出版商 GlobalData 商品編碼 328415
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
Back to Top
胰岛细胞癌 (胰島素瘤) :全球臨床實驗趨勢 Islet Cell Carcinoma (Insulinoma) Global Clinical Trials Review, H1, 2015
出版日期: 2015年02月27日 內容資訊: 英文 106 Pages
簡介

本報告提供全球胰岛细胞癌 (胰島素瘤) 治療藥臨床實驗相關調查,提供您各地區的臨床試驗數資料,實驗階段,實驗狀況,採用主題及各類型贊助企業的臨床實驗資料,中斷 (暫時停止、廢止、停止) 的實驗清單等資訊。

簡介

  • 胰岛细胞癌 (胰島素瘤)
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要國家的臨床實驗數量
    • 中南美主要國家的臨床實驗數量

G7各國臨床實驗數量:癌症治療藥臨床實驗上胰岛细胞癌 (胰島素瘤) 的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:癌症治療藥臨床實驗上胰岛细胞癌 (胰島素瘤) 的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

未完成的臨床實驗數量

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

胰岛细胞癌 (胰島素瘤) 治療藥臨床實驗的主要參與企業

有潛力的藥劑

臨床實驗簡介

  • 主要企業臨床實驗概要
    • Novartis AG
    • Pfizer Inc.
    • Eli Lilly and Company
    • XOMA Corporation
    • Burzynski Research Institute, Inc.
  • 有代表性的研究機關·醫院臨床實驗概要
    • National Cancer Institute
    • Eastern Cooperative Oncology Group
    • Memorial Sloan Kettering Cancer Center
    • Vanderbilt-Ingram Cancer Center
    • Northwestern University
    • University of Southern California
    • The National Institute of Diabetes and Digestive and Kidney Diseases
    • Sidney Kimmel Comprehensive Cancer Center
    • Stanford University

5個有代表性的臨床實驗簡介

附錄

目錄
Product Code: GDHC2587CTIDB

GlobalData's clinical trial report, "Islet Cell Carcinoma (Insulinoma) Global Clinical Trials Review, H1, 2015" provides data on the Islet Cell Carcinoma (Insulinoma) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Islet Cell Carcinoma (Insulinoma). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Islet Cell Carcinoma (Insulinoma). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Islet Cell Carcinoma (Insulinoma)
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Islet Cell Carcinoma (Insulinoma) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Islet Cell Carcinoma (Insulinoma) to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Islet Cell Carcinoma (Insulinoma)
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Eli Lilly and Company
      • Clinical Trial Overview of Eli Lilly and Company
      • XOMA Corporation
      • Clinical Trial Overview of XOMA Corporation
      • Burzynski Research Institute, Inc.
      • Clinical Trial Overview of Burzynski Research Institute, Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • Eastern Cooperative Oncology Group
      • Clinical Trial Overview of Eastern Cooperative Oncology Group
      • Memorial Sloan Kettering Cancer Center
      • Clinical Trial Overview of Memorial Sloan Kettering Cancer Center
      • Vanderbilt-Ingram Cancer Center
      • Clinical Trial Overview of Vanderbilt-Ingram Cancer Center
      • Northwestern University
      • Clinical Trial Overview of Northwestern University
      • University of Southern California
      • Clinical Trial Overview of University of Southern California
      • The National Institute of Diabetes and Digestive and Kidney Diseases
      • Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases
      • Sidney Kimmel Comprehensive Cancer Center
      • Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center
      • Stanford University
      • Clinical Trial Overview of Stanford University
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Clinical Trials by Region, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015*
  • Proportion of Islet Cell Carcinoma (Insulinoma) to Oncology Clinical Trials, G7 Countries (%), 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Islet Cell Carcinoma (Insulinoma) to Oncology Clinical Trials, E7 Countries (%), 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Suspended Clinical Trials, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Withdrawn Clinical Trials, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Terminated Clinical Trials, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by XOMA Corporation, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by Burzynski Research Institute, Inc., 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt-Ingram Cancer Center, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Southern California, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2015*

List of Figures

  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, North America, Top Countries (%), 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015*
  • Proportion of Islet Cell Carcinoma (Insulinoma) to Oncology Clinical Trials, G7 Countries (%), 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Islet Cell Carcinoma (Insulinoma) to Oncology Clinical Trials, E7 Countries (%), 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Islet Cell Carcinoma (Insulinoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Back to Top